The announcement was made during trading hours today, 28 June 2013.
Meanwhile, the S&P BSE Sensex was up 324.20 points or 1.72% at 19,200.15.
On BSE, 1.58 lakh shares were traded in the counter as against average daily volume of 82,440 shares in the past one quarter.
The stock hit a high of Rs 25.70 and a low of Rs 23.55 so far during the day. The stock had hit a 52-week high of Rs 35.25 on 13 December 2012. The stock had hit a 52-week low of Rs 13.75 on 27 June 2012.
The stock had outperformed the market over the past one month till 27 June 2013, sliding 4.7% as compared to the Sensex's 5.77% fall. The stock had also outperformed the market in the past one quarter, gaining 3.1% as compared to the Sensex's 0.92% rise.
The small-cap company has equity capital of Rs 11.68 crore. Face value per share is Re 1.
Suven Life Sciences (Suven) said that the two product patents are valid through 2028 & 2029. The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia, Suven said in a statement.
With these new patents, Suven has a total of six granted patents from Japan and twelve granted product patents from United States. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II, Suven said in a statement.
Venkat Jasti, CEO, Suven Life Sciences said, "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally".
Suven Life Sciences' net profit rose 20.7% to Rs 8.63 crore on 18.8% growth in net sales to Rs 74.70 crore in Q4 March 2013 over Q4 March 2012.
Suven Life Sciences is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. The company has twelve internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.
Powered by Capital Market - Live News
